Company Overview: Inovio Pharmaceuticals is a clinical stage biotech company focused on developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, with a robust pipeline of therapeutic and vaccine candidates.
Lead Program Update: The company's lead program, INO-3107, aims to treat recurrent respiratory papillomatosis (RRP) and has received breakthrough therapy and orphan drug designations from the FDA, with a BLA submission expected in the second half of the year.
INO
$2.32+Infinity%1D
Analyst Views on INO
Wall Street analysts forecast INO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INO is 7.33 USD with a low forecast of 3.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast INO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INO is 7.33 USD with a low forecast of 3.00 USD and a high forecast of 13.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.260
Low
3.00
Averages
7.33
High
13.00
Current: 2.260
Low
3.00
Averages
7.33
High
13.00
Piper Sandler
Edward Tenthoff
Overweight
maintain
$5 -> $6
2025-11-14
Reason
Piper Sandler
Edward Tenthoff
Price Target
$5 -> $6
2025-11-14
maintain
Overweight
Reason
Piper Sandler analyst Edward Tenthoff raised the firm's price target on Inovio to $6 from $5 and keeps an Overweight rating on the shares. The firm notes the company ended Q3 with cash of $50.8M and subsequently raised gross proceeds of $28.75M bringing pro forma cash to $77.3M, expected to fund operations into Q3 2026 through INO-3107 approval.
Piper Sandler
Edward Tenthoff
initiated
$5
2025-07-09
Reason
Piper Sandler
Edward Tenthoff
Price Target
$5
2025-07-09
initiated
Reason
Piper Sandler analyst Edward Tenthoff initiated coverage of Inovio with an Overweight rating and $5 price target. The company is is developing DNA-encoded medicines to treat cancer, infectious and rare diseases, the analyst tells investors in a research note. The firm says INO-3107, being developed to treat recurrent respiratory papillomatosis caused by human papillomavirus, was well tolerated and achieved robust clinical efficacy in a Phase I/II study.
Oppenheimer
Oppenheimer
Outperform
downgrade
$15 -> $13
2025-05-14
Reason
Oppenheimer
Oppenheimer
Price Target
$15 -> $13
2025-05-14
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Inovio to $13 from $15 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 2025 results with $25.1M OpEx and cash balance of $68.4M, which is expected to provide runway into Q1 2026. Encouragingly, Inovio remains on track to initiate rolling BLA submission for INO-3107 in mid-2025, and subsequent filing completion in the second half of 2025 could support potential approval as early as mid-2026 if granted priority review, Oppenheimer adds.
HC Wainwright & Co.
Raghuram Selvaraju
Hold
Reiterates
$3
2025-03-19
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$3
2025-03-19
Reiterates
Hold
Reason
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
